All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA(1C) and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia. Patients with uncontrolled diabetes might be treated by the complementary action of insulin plus DPP-4 inhibitors. Here, we compa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Endocr Disord
Egile Nagusiak: Yen, Fu-Shun, Chiang, Jen-Huai, Hwu, Chii-Min, Yen, Yu-Hsin, Lin, Boniface J., Wei, James Cheng-Chung, Hsu, Chih-Cheng
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6321656/
https://ncbi.nlm.nih.gov/pubmed/30611254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-018-0330-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak